This clinical trial is focused on studying the long-term effects of a treatment called XTMAB-16 for patients with pulmonary sarcoidosis. Pulmonary sarcoidosis is a condition where clusters of inflammatory cells, known as granulomas, form in the lungs, and it can sometimes affect other parts of the body. The treatment being tested, XTMAB-16, is given as a solution through an intravenous infusion, which means it is administered directly into the bloodstream through a vein.

The purpose of this study is to evaluate the long-term safety and effectiveness of XTMAB-16 in managing pulmonary sarcoidosis, whether or not it involves other parts of the body. Participants in the study will receive the treatment over an extended period, and researchers will monitor them to see how well they tolerate the medication and how it affects their condition. The study will also look at various health measures, such as lung function and quality of life, to understand the overall impact of the treatment.

Throughout the study, researchers will keep track of any side effects or adverse events that participants may experience. They will also assess changes in the use of corticosteroids, which are often used to manage sarcoidosis symptoms, and measure certain biological markers in the blood that can indicate inflammation or disease activity. This information will help determine the long-term benefits and risks of using XTMAB-16 for treating pulmonary sarcoidosis.